Large changes occur in the amount, metabolic stability, and distribution of the AChR during the maturation process of the neuromuscular junction as well as after muscle denervation (for reviews, see references 26, 31, 56, 15) . Some of these changes involve alterations in the rates of synthesis, degradation, and incorporation of the receptor into the surface membrane. The biochemical nature of both synthesis (2, 19, 20, 30, 35, 53, 54) and degradation (12, 22, 23, 25, 27, 46, 47, 57, 59) has been the focus of numerous studies.
In addition to their possible involvement in synaptogenesis, changes in the degradation rate of AChR may play an important role in the cause of the neuromuscular disease, myasthenia gravis. Sera from patients with this disease contain antibodies to the AChR (48) , and the interaction of antibodies with the receptor is thought to be at least partly responsible for the pathogenesis of the disease (for reviews, see references 29, 49, 50) . Antibodies to AChR induce an abnormally rapid rate of turnover of the AChR in muscle (5, 14, 35, 37, 43, 55) . The subsequent decrease in the synaptic content of AChR contributes to the failure of synaptic transmission at affected muscles. Much of the information concerning the cellular degradation pathway of AChR is based on morphological studies. A more detailed understanding of the biochemical mechanisms of degradation could be beneficial to efforts in developing treatments for myasthenia gravis.
A study of the cellular mechanism of AChR turnover is of interest in a more general sense as a model system for the degradation of transmembrane proteins. The metabolic fate of cell surface membrane receptors and their ligands has been studied in a variety of experimental systems including the Tissue Culture: BC3H-1 cells were cultured as described by Patrick et al. (57) . Ceils were passaged every 4 d in order to maintain logarithmic phase of growth. Cells were plated at 2 x 10a/cm 2 on 60-ram plastic tissue culture dishes. For turnover studies, cells were allowed to enter stationary phase growth and were used within 10 d of passage.
Enzyme Assays: N-Acetyl-fl-glucosammidase (NAflGase) was assayed using the methylumbelliferyl-derivatized substrate according to the method of Barrett (10) with slight modifications. The t-real incubation mixture contained 4-methyhimbelliferyl N-acetyl-fl-D-ghicosaminidine (0.5 raM), sucrose (0.25 M), Triton X-100 (0.33%), 0.1 M sodium citrate, pH 5.0, and bovine serum albumin (BSA) (0.17 mg/ml). The reaction was initiated by the addition of enzyme and terminated by the addition of bicarbonate-carbonate stop solution after incubation for 9 mm at 37°C. Reaction product was detected fluorometricaUy with an excitation beam of 375 am and emission measured at 460 nm. To construct a standard curve, 0.25 ml of methylumbelliferone solutions in the concentration range of 0.0025-0.025 mM were included in reaction mixtures instead of the enzyme. Protein was determined according to the method of Bradford (17) with manor modifications. Samples ( 100/.il) containing 0.15-2.5 ng protein were mixed with 0.5 ml of the protein reagent and the As~ was determined. BSA standards HYMAN AND FRO[HNER were used to generate a standard curve. To measure the protein content of samples that contained Percoll, aliquots were made 0.5% in SDS and incubated at 25°C for 1 h. The samples were then centrifuged in a Beckman LP42 rotor (Beckman Instruments, Inc., Fullerton, CA) at 28,500 rpm for 1 h to pellet the Percoll. Samples (20 #1) of the supernatants were analyzed as described by Bramhall et al. (18) .
AChR Turnover Experiments:
Procedures similar to those described by Patrick et al. (57) were used. To label surface AChR of BC3H-I cells, cultures were incubated in Dulbecco's Modified Eagle's Medium (DME), 0.2% FCS (0.2% DME) containing 1 x 10 -a M [~2aI]a-BuTx for one h at 37°C, washed to remove unbound toxin, and placed in growth medium. At various time intervals, duplicate aliquots of culture medium were removed and replaced with fresh medium. Radioactivity in the aliquots was determined in a gamma 4000 counter (Beckman Instruments Inc.). At the end of the incubation period, the cultures were washed two times with 2 ml of 138 mM NaCI, 3 mM KC1, 8.15 mM Na2HPO4, 1.47 mM KH2PO4 (NaCI/PI) and the ceils were collected by centrifugation in a microfuge (Beckman Instruments Inc.). Cell pellets were then counted. The radioactivity associated with ceils at the beginning of the experiment was calculated by summing that found in the cell pellet with that in the medium. Chromatography of an aliquot of the medium on a Bin-Gel P-2 column verified that the radioactivity excreted by the cells had the properties of [~ZSl]tyrosine (13) (data not shown). Degradation half-times of toxin-receptor complexes were determined by plotting the percentage of radioactivity which remained cellassociated on a semilog scale against time of incubation. The rate of [~2~l]a-BuTx dissociation from the receptors is slow compared with the rate of degradation (59) .
Quantitation of AChR Pools: BC3H-1 ceils have, in addition to a surface population of AChR, two discrete internal pools of AChR (57) . Methods similar to those described by Patrick et al. (57) were used to quantitate these AChR receptor populations. Surface AChR was determined by binding [x2sI]c~-BuTx (10 -n M for 60 rain) to cells and washing out unbound toxin as described above. Nonspecific [~2Sl]a-BuTx binding, defined as the binding that occurred in the presence of 2 X 10 -s M a-BuTx or 0.1 mM d-tubocurarine (dTc), was < 11~o. The labeled cells were harvested from the dish and centrifuged in a table top clinical centrifuge for 10 rain at 1,000 rpm. The cell pellet was extracted for 3 h on ice in 0.2 ml NaC1/P~ containing 1% Triton X-100, I mM EDTA (1% NaCI/ Pi). After centrifugation of the extract at 1,000 rpm for 10 rain, aliquots of the labeled extract were then counted directly or after filtration through DEAE falters. To quantitate total internal AChR, cell surface receptors were first blocked with unlabeled c~-BuTx (10 -s M for 60 rain) and excess toxin was removed by washing. Triton extracts were then prepared, 20/A was incubated with 10 -8 M [12~I]a-BuTx for 30 rain at 37°C, and the amount of complex formed was determined by DEAE •ter assay similar to that described by Schmidt and Raftery (61 ) . The internal AChR is composed of two pools, a precursor to surface component and a hidden pool of unknown characteristics (57) . The hidden pool was quantitated after cycloheximide depletion of the precursor to surface population from the total internal pool as in Patrick et al. (57) . Following saturation of surface AChR with ct-BuTx, ceils were washed, harvested, and extracted as above. Quantitation of the AChR in the extracts was carried out by DEAE filter assay. The size of the precursor to surface component was calculated as the difference between the total internal pool and the hidden pool. Total cellular AChR was determined by DEAE filter assay of an untreated cell extract.
In some cases, a spinning column toxin binding assay was employed. Samples of Triton extracts (400 pl) containing 3 × 10 -9 M. [~2~l]a-BuTx were incubated at 37°C for 90 rain. Bin-Gel P-30 columns were prepared in 3-ml syringes, equilibrated with 50 mM Tris C1, 0.1% Triton X-100, 1 mg/ml BSA, pH 7.4, and then centrifuged for 5 min at 1,000 rpm. The reaction mixture was appLied to the column and the spin was repeated. The fluid that passed through the columns was counted. Lower molecular weight components such as unbound a-BuTx were retained by the column, whereas higher molecular weight material such as toxin-receptor complexes eluted in the void volume. Nonspecific binding (the binding that occurred after preincubation in the presence of saturating concentrations of a-BuTx or 0.1 mM dTc) was subtracted.
Subcellular Fractionation of BC3H-1 Ceils: Cells were washed, harvested from the plates, and centrifuged in a clinical centrifuge as described above. The cell pellet was then suspended in 6 ml 1 mM triethanolamine, 0.25 M sucrose, pH 7.2 (tetraethylammohium [TEA] sucrose), and homogenized in a 17-ml zero clearance homogenizer for three strokes at 4°C using a motor-driven pestle. The homogenate was then spun in a centrifuge (model JA 20; Beckman Instruments Inc.) for 10 rain at 1700 g. The supernatant was recovered and centrifuged at 33,000 g for 60 rain. The high speed pellet was resnspended in 1.0 ml TEA sucrose and applied to a 25% vol/vol Percoll gradient which was prepared as follows: 2.5 ml 2.5 M sucrose was placed in the bottom of type 60 Ti centrifuge tube and was overlaid with 20 ml of a 25% vol/vol isoosmotic PercoU (d = 1.126 g/cm3)/TEA sucrose solution. The gradient was then centrifuged in a type 60 Ti rotor for 20 rain at 45,000 g with low acceleration, l-ml fractions were coLiected from the top. Densities were determined by the use of a density
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marker bead kit. Fractions were assayed for radioactivity and NA/~Gase activity. In some experiments, the desired fractions were pooled and ehromatographed on a 0.7 x 75 cm Sephacryl S-1000 column. Fractions (1.5 ml) were collected and assayed for radioactivity and NA/3Gase. The appropriate fractions were pooled and concentrated by one of two methods. Pooled material was centrifuged over a 1.0-ml cushion of 2.5 M sucrose for 60 rain at 33,000 g. The material at the interface was collected in a minimal volume and diluted with 1.0 mM triethanolamine, pH 7.2, to the desired final sucrose concentration. Samples prepared in this manner were subsequently used for further fractionation purposes. Alternatively, the sample was centrifuged over a 1.0-ml cushion of maxidens oil for 60 rain at 33,000 g. The material at the interface was collected and made 1.0% in Triton X-100, and extracted on ice for 1 h. This material was used in subsequent velocity gradient sedimentation experiments. Samples intended for further subcellular fractionation studies were layered over 11.0 ml, 20--42% (wt/vol) metrizamide gradients and centrifuged at 50,000 g for 18 h as described by Aas (1). lml fractions were collected from the top and analyzed for radioactivity, NA//Gase activity, and protein. The extracted samples to be analyzed by velocity gradient sedimentation were layered on 4.4 ml, 5-20% (wt/vol) sucrose gradients prepared in 1% NaCI/P~. The gradients were centrifuged at 102,000 g for 20 h in a rotor (modal SW 56; Beckman Instruments, Inc.) and 180-p.1 fractions were collected by puncturing the bottom of the tube. The fractions were then analyzed for radioactivity.
RESU LTS
Work from several laboratories has shown that the degradation rate of cell surface AChR can be measured by reacting them with [~25I]a-BuTx and then monitoring the appearance in the culture medium of ~2~I-monoiodotyrosine (12, 13, 57) . The turnover rate of the toxin-receptor complex is very similar to that of the unbound receptor (34, 52) . In reasonable agreement with results from other laboratories, we found that AChR in BC3H-1 cells are degraded with a haft-time of ~ 11-16 h (Figs. 1 and 2). Radioactivity in the medium was identified as monoiodotyrosine by comparing its elution position on Bio-Gel P-2 with that of a standard (data not shown). Treatment of the cells with the lysosomal protease inhibitor, leupeptin, inhibits AChR degradation in a dose-dependent manner (Fig. I) . The t~/2 for degradation was increased two-to sixfold, depending on the concentration of leupeptin present. The half-time of degradation as well as the sensitivity to leupeptin varied somewhat with the stock of cells used and the time after plating.
It was important to determine whether this inhibition was reversible. For this purpose a turnover-recovery experiment ( Fig. 2 ) was carded out. Surface AChR were labeled with [~25I]a-BuTx and incubated in medium containing 60 #M leupeptin. Half of the cultures exposed to leupeptin were washed free of inhibitor after 19-h exposure and were incubated in control media. The results show that cultures treated in this manner regain a turnover rate similar to that of the control cultures within 20 h of the media change.
In addition to AChR on the cell surface, there exists an internal pool of receptor which can be measured after blocking cell surface AChR with unlabeled a-BuTx (57) . Previous work has shown that the internal pool is composed of at least two components. One component is a precursor to surface pool which is depletable from its internal location by cycloheximide treatment and presumably represents newly synthesized AChR in transit to the plasma membrane. The other component, termed the hidden pool, appears to be at no time accessible to the external milieu and has no assigned function. Since cultures exposed to leupeptin contained more AChR than control ceils, it was important to determine which population of receptor was augmented. After a 19-h incubation in the presence of 40 ~M leupeptin, the amount of internal AChR measured after depleting the surface precursor component was increased approximately two-fold (Table I) 
h) (V). The radioactivity released
into the media was measured at the times indicated, and the data were used to calculate the turnover rates. ments demonstrates that an internally located pool with some of the characteristics of the hidden pool is augmented by leupeptin treatment.
Additional results indicate, however, that the leupeptin-augmented pool is distinct from the pre-existing hidden pool. Cultures were exposed to control or leupeptin-containing media (60 /~M), in both the presence and absence of excess, unlabeled a-BuTx. After depletion of the surface precursor pool by cycloheximide treatment, the amounts of internal receptors were measured. Receptors that are derived from the cell surface during the exposure to unlabeled a-BuTx would be blocked and, therefore, silent in a soluble toxin binding assay. Table II shows that a 24-h incubation in the presence of 60 laM leupeptin causes a three-fold buildup in the internal AChR. In control cultures, the size of the hidden pool is unaffected by the presence of excess a-BuTx in the culture medium. This is in agreement with the results of Patrick et al. (57) :l: Cells were exposed to 60/~M leupeptin for 24 h. § Unlabeled toxin (2 x 10 -a M) was present in the medium. ¶ Average of duplicate determinations {4-7% variation in range).
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incubation is too short to allow detectable internalization. Finally, the cells were harvested, homogenized, and analyzed by Percoll rate zonal gradient centrifugation. Cultures that were prelabeled and treated with control media show a single peak of radioactivity near the top of the gradient (Fig. 3A) . This material represents plasma membrane since it is found also in postlabeled cells (Fig. 3 C) . The amounts of plasma membrane AChR in the latter two cultures are very nearly identical, substantiating the results from the pool quantitation experiments (Table I) . Gradient profiles from prelabeled cultures treated with leupeptin contain, in addition to the surface membrane AChR, a denser peak of radioactivity (Fig. 3 B) . This material sediments reproducibly as a peak in fractions 16-20 (1.07-1.13 g/cm3), which is coincident with the NaflGase activity, a marker enzyme for lysosomes. The enzyme activity of the peak fractions was 70% latent as measured by its activity in the absence of Triton. The dense material does not arise from artifactual vesiculation of specialized regions of the plasma membrane during homogenization since it is not found in postlabeled, leupeptin-treated cultures. Thus, leupeptin inhibition of AChR turnover causes a build up of a population of AChR which comigrates with the lysosomal component of these cells on Percoll gradients.
Further purification of the lysosomal component from prelabeled leupeptin-treated cultures has been carded out in an attempt to determine whether the leupeptin-augmented AChR reside in lysosomes or in some other cellular compartment which co-migrates with lysosomes on Percoil gradients. Before additional purification techniques could be employed, however, it was necessary to remove the Percoll from the NAflGasecontaining cellular material. Gel fdtration chromatography on Sephacryl S-1000 was used to separate the subceilular material from the Percoll. Percoll particles have a mean diameter of 35 nm and therefore elute within the included volume while the cellular material elutes in the void volume measured by the elution position of 795-nm-diam beads (arrow, Fig. 4A ). Both the radioactivity and the NAflGase activity from the Percoll gradient dense material of prelabeled cultures treated for 16 h with 15-#M leupeptin elute in the void volume (300-400-nmdiam exclusion limit). The peak fractions were pooled, concentrated, and applied to continuous 20-42% metrizamide gradients for further fractionation by equilibrium density gradient centrifugation. Profdes of the radioactivity, NAflGase activity, and protein distribution of this purification step are shown in Fig. 4 B. Radioactivity peaks and NAflGase activity, although rather broad, remain coincident. The density of the peak fraction is 1.15 g/cm 3, which is in agreement with the values found by others for the density of lysosomes in this medium (1) . Total purification of the lysosomal fraction was 10-17-fold, based on the relative specific activity of NAflGase.
Separation of the plasma membrane AChR from those in the presumptive lysosomal compartment on Percoll gradients allowed a comparison of the biochemical characteristics of the two receptor populations in leupeptin-treated cells. The sedimentation behavior of the two populations on sucrose velocity gradients containing Triton was examined. Following chromatography on Sephacryl S-1000 columns, samples were concentrated, solubilized with Triton, and applied to 5-20% sucrose gradients. Purified Torpedo californica AChR, BC3H-I plasma membrane receptor samples, and leupeptin-augmented material were run in parallel (Fig. 5) . As expected, virtually all of the plasma membrane receptor sediments coincidentally Our results suggest that AChR in leupeptin-treated BC3H-1 cells accumulates in lysosomes. The Percoll gradients used in this study afforded a clear resolution of plasma membrane from lysosomes. The accumulated labeled material observed in leupeptin-treated, prelabeled cultures co-migrated with a lysosomal enzyme marker, NABGase, and these activities remained coincident throughout two additional purification steps. The possibility that the radio-labeled material is contained in a contaminating cellular compartmen t which comigrates with lysosomes is not excluded by these findings since lysosomes were not purified to homogeneity. In view of the coincident behavior of accumulated AChR and NAflGase activity however, it is reasonable to assume that the AChR accumulation in leupeptin-treated BC3H-1 cells occurs in the lysosome. Other laboratories have reported that leupeptin plus pepstatin inhibits AChR degradation and suggested on this basis that receptor turnover proceeds via a lysosomal pathway (55) . Our results showing accumulation of internalized AChR in a compartment with lysosomal characteristics provide further support for this proposal.
Libby et al. (46) reported a study of the effects of leupeptin and other inhibitors on AChR turnover in cultured chick muscle cells. In their system, leupeptin inhibited AChR degradation and caused the accumulation of an internal pool of receptors. The cellular compartment containing these AChR was sedimentable at 35,000 g. Ultrastructurat studies indicated that leupeptin-treated cells contained three times as many coated vesicles as control cells and, on this basis they suggested that the accumulated AChR reside in coated vesicles. Using horseradish peroxidase conjugated-a-BuTx, Bursztajn and Fischbach (24) identified coated vesicles containing AChR in chick muscle ceils treated with an extract of chick brain. However, only -20% of these coated vesicles became labeled in a l-6-h incubation of the myotubes with the toxin conjugate. Thus, most of them are not derived from the surface. These results neither demonstrate nor discount a possible involvement of coated vesicles in the AChR degradation pathway. Similarly, the evidence we present here does not rule out a coated vesicle step in the turnover process. Untreated chick myotubes are known to contain an internal pool of AChR derived from the cell surface (27) . This permitted an autoradiographic study which demonstrated that, in cells labeled with [x25I]c~-BuTx, structures resembling secondary lysosomes contain radioactivity (28) . A final resolution of the cellular location of internalized AChR in leupeptin-treated ceils as well as elucidation of the steps in the degradative pathway will require an autoradiographic study at the ultrastructural level.
The possibility that the radioactivity observed to accumulate due to leupeptin treatment does not represent internalized aBuTx-AChR complexes but instead merely traces the path of dissociated or degraded toxin is excluded by the result obtained in the sucrose velocity gradient centrifugation studies. Twothirds of the label from the NAflGase coincident material recovered from the PercoU gradients sedimented in a position near 9S, the characteristic sedimentation behavior of monomeric Torpedo and mammalian AChR. It should be noted that in some cases the sedimentation patterns of intact and proteolyzed AChR are very similar (51) . Thus, this portion of the AChR from the lysosomal fraction is not necessarily unmodified. The remainder sedimented as a very high molecular weight form which may be an important degradative intermediate. In a previously published report (44) , the study of the degradation of proteins containing an amino acid analogue in the rabbit reticulocyte system revealed the formation of intracellular aggregates, one-third of which was sedimented by a 10,000 g centrifugation. This high molecular weight form may be an analogous degradative intermediate to that portion of the leupeptin-augmented, NAflGase coincident AChR that behaves as an aggregate. Whether AChR aggregates actually exist in the cell or whether they represent modified receptors that are more prone to aggregation after Triton solubilization remains to be determined. Further studies will be required in order to examine in more detail the characteristics of this material.
A hidden pool of AChR in BC3H-1 ceils has been described (57) as a portion of an internal pool which does not appear to function as a surface precursor and is not accessible to the external milieu at any time. This receptor population has no assigned function, nor is its cellular location known. After solubilization, receptors from the hidden pool have a sedimentation coefficient 0.5--0.6S lower than surface receptors (57) . Leupeptin inhibition of AChR turnover does not change the hidden pool size but rather causes an accumulation of a receptor subpopulation that is surface derived. Subcellular fractionation studies demonstrated a further distinction between the hidden and leupeptin-augmented pools. A clear resolution of the hidden pool from the NAflGase coincident, leupeptin-augmented AChR was obtained on Percoll gradients. The hidden pool of receptor migrated to a position that is less dense than the lysosomal peak and of greater density than the position of plasma membrane. It is not known however, in what cellular compartment the hidden pool resides. More sensitive assays for other enzyme markers are needed in this system before this question can be answered.
Morphological studies of internalized ct-BuTx-AChR complexes have provided most of the information concerning the pathway of AChR degradation. Electron microscopic autoradiographic studies of AChR labeled with [12sI]ct-BuTx have shown that most receptors reside on the cell surface (45, 60) , although some cytoplasmic staining has been observed as well. Intracellular AChR have been observed associated with Golgi apparatus (6, 30) , lysosomes (28) , coated vesicles (24) , and multivesicular bodies (6) . The details of the involvement of these intracellular compartments in AChR degradation remain to be elucidated. The biochemical approach that we have described here should be a useful complement to the morphological studies. In particular, it should now be possible to examine the effects of other inhibitors that may block the pathway at different steps.
